RE:BTD Tend to agree that it was that blue blob of BTD right at the end of 2022 that led to general disappointment yesterday John but maybe not wise for a small Biotech to presume anything from the FDA and the prediction as a consequence possibly conservative?
Something has made them concentrate on NSCLC exclusively for the next indication. Have they found a combination of intravenous Rutherrin and external X-Ray that is both efficacious and repeatable in lung cancer? Might this eventually induce an immune response? Could we be looking at something special here?
They’ve been using intravenous Rutherrin with impressive results for well over 5 years` now but apparently it’s still ‘in development’ for human use.
This - and the fact that they appear in consequence to have dropped a commitment to any sort of Phase IB in 2022 - was the personal disappointment.